CytoMed Therapeutics (GDTC) Accounts Payables (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Accounts Payables for 5 consecutive years, with $342478.0 as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 3.3% to $342478.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $342478.0 through Dec 2025, up 3.3% year-over-year, with the annual reading at $345180.0 for FY2025, 6.93% up from the prior year.
  • Accounts Payables hit $342478.0 in Q4 2025 for CytoMed Therapeutics, up from $331550.7 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $388585.0 in Q4 2023 to a low of $161181.9 in Q4 2021.
  • Historically, Accounts Payables has averaged $304767.2 across 5 years, with a median of $331550.7 in 2024.
  • Biggest five-year swings in Accounts Payables: surged 86.15% in 2022 and later dropped 14.68% in 2024.
  • Year by year, Accounts Payables stood at $161181.9 in 2021, then surged by 86.15% to $300040.6 in 2022, then rose by 29.51% to $388585.0 in 2023, then decreased by 14.68% to $331550.7 in 2024, then increased by 3.3% to $342478.0 in 2025.
  • Business Quant data shows Accounts Payables for GDTC at $342478.0 in Q4 2025, $331550.7 in Q4 2024, and $388585.0 in Q4 2023.